EuroQol-5 dimensions utility gain according to British and Swedish preference sets in rheumatoid arthritis treated with abatacept, rituximab, tocilizumab, or tumour necrosis factor...

por Gülfe, Anders, Wallman, Johan K., Kristensen, Lars Erik
Publicado 2016

Elevated fecal levels of the inflammatory biomarker calprotectin in early systemic sclerosis

por Hamberg, Viggo, Wallman, Johan K., Mogard, Elisabeth, Lindqvist, Elisabet, Olofsson, Tor, Andréasson, Kristofer
Publicado 2022

Comparison of non-radiographic axial spondyloarthritis and ankylosing spondylitis patients – baseline characteristics, treatment adherence, and development of clinical variables du...

por Wallman, Johan K., Kapetanovic, Meliha C., Petersson, Ingemar F., Geborek, Pierre, Kristensen, Lars Erik
Publicado 2015

Gut dysbiosis associated with worse disease activity and physical function in axial spondyloarthritis

por Sagard, Jonas, Olofsson, Tor, Mogard, Elisabeth, Marsal, Jan, Andréasson, Kristofer, Geijer, Mats, Kristensen, Lars Erik, Lindqvist, Elisabet, Wallman, Johan K.
Publicado 2022

Methotrexate treatment in early psoriatic arthritis in comparison to rheumatoid arthritis: an observational nationwide study

por Lindström, Ulf, di Giuseppe, Daniela, Exarchou, Sofia, Alenius, Gerd-Marie, Olofsson, Tor, Klingberg, Eva, Jacobsson, Lennart, Askling, Johan, Wallman, Johan K
Publicado 2023

A Multi‐Biomarker Disease Activity Score and the Choice of Second‐Line Therapy in Early Rheumatoid Arthritis After Methotrexate Failure

por Hambardzumyan, Karen, Saevarsdottir, Saedis, Forslind, Kristina, Petersson, Ingemar F., Wallman, Johan K., Ernestam, Sofia, Bolce, Rebecca J., van Vollenhoven, Ronald F.
Publicado 2017

Infliximab Versus Conventional Combination Treatment and Seven‐Year Work Loss in Early Rheumatoid Arthritis: Results of a Randomized Swedish Trial

por Eriksson, Jonas K., Wallman, Johan K., Miller, Heather, Petersson, Ingemar F., Ernestam, Sofia, Vivar, Nancy, van Vollenhoven, Ronald F., Neovius, Martin
Publicado 2016

Association of a multibiomarker disease activity score at multiple time-points with radiographic progression in rheumatoid arthritis: results from the SWEFOT trial

por Hambardzumyan, Karen, Bolce, Rebecca J, Saevarsdottir, Saedis, Forslind, Kristina, Wallman, Johan K, Cruickshank, Scott E, Sasso, Eric H, Chernoff, David, van Vollenhoven, Ronald F
Publicado 2016

Secukinumab efficacy on resolution of enthesitis in psoriatic arthritis: pooled analysis of two phase 3 studies

por Coates, Laura C., Wallman, Johan K., McGonagle, Dennis, Schett, Georg A., McInnes, Iain B., Mease, Philip J., Rasouliyan, Lawrence, Quebe-Fehling, Erhard, Asquith, Darren L., Fasth, Andreas E. R., Pricop, Luminita, Gaillez, Corine
Publicado 2019

Is the risk of infection higher during treatment with secukinumab than with TNF inhibitors? An observational study from the Nordic countries

por Glintborg, Bente, Di Giuseppe, Daniela, Wallman, Johan K, Provan, Sella A, Nordström, Dan, Hokkanen, Anna-Mari, Österlund, Jenny, Kristianslund, Eirik, Kvien, Tore K, Gudbjornsson, Bjorn , Hetland, Merete Lund, Michelsen, Brigitte, Jacobsson, Lennart, Askling, Johan , Lindström, Ulf
Publicado 2022